A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/28/2018 |
| Start Date: | December 19, 2017 |
| End Date: | July 29, 2022 |
An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia
The purpose of this study is to investigate the safety of patients in Asia with Non-Small
Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third
line treatment.
Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third
line treatment.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Advanced metastatic stage IIIB/IV NSCLC (Nonsquamous and squamous)
- 1 to 2 prior systemic therapies
- Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to
1
- Participants must have measurable disease by computed tomography (CT) or magnetic
resonance imaging (MRI)
- Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to
starting study treatment
Exclusion Criteria:
- Women with a positive pregnancy test at enrollment or prior to administration of study
medication
- Participants with active central nervous system metastases
- Participants with a condition requiring systemic treatment with either corticosteroids
(> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
days of first dose of study drug
- Participants with previous malignancies are excluded unless a complete remission was
achieved at least 2 years prior to study entry AND no additional therapy is required
or anticipated to be required during the study period
- Participants with carcinomatous meningitis
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials